Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study

Martina Patone, Karen Thomas, Robert Alan Hatch, Pui San Tan, Carol Coupland, Weiqi Liao, Paul Mouncey, David A Harrison, Kathy Rowan, Peter Horby, Peter Watkinson, Julia Hippisley–CoxThe Lancet Infectious Diseases 2021 · DOI

TL;DR

A large observational study in England found that the SARS-CoV-2 B.1.1.7 variant (Alpha) was associated with a significantly increased risk of critical care unit (CCU) admission and 28-day mortality compared to non-B.1.1.7 variants. However, for patients who were admitted to critical care, the virus lineage did not appear to influence their mortality risk.

What Problem Does This Paper Address?

The emergence of new SARS-CoV-2 variants, particularly lineage B.1.1.7 (first identified in the UK in late 2020), raised significant public health concerns due to its increased transmissibility. Early studies suggested B.1.1.7 might also be associated with a higher risk of mortality, but there was uncertainty due to limitations in adjusting for confounding factors and a lack of clarity on its impact on critical care outcomes. This study aimed to rigorously quantify the association between B.1.1.7 and the risk of critical care admission and mortality, controlling for a wide range of patient characteristics.

Methods

This was a large-scale observational cohort study that linked several national health databases in England. The researchers used S-gene target failure (SGTF) as a proxy for the presence of the B.1.1.7 lineage, as this variant exhibits a specific S-gene deletion.

Two main cohorts were analyzed:

  1. Primary Care Cohort: Patients with a positive community COVID-19 test between November 1, 2020, and January 26, 2021, with known SGTF status. This cohort was used to assess the risk of CCU admission and 28-day mortality.
  2. Critical Care Cohort: Patients admitted to critical care with a positive community COVID-19 test between November 1, 2020, and January 27, 2021, with known SGTF status. This cohort was used to assess mortality risk within critical care.

Statistical analysis primarily employed flexible parametric survival models (Royston-Parmar models) to estimate hazard ratios (HRs) for CCU admission and 28-day mortality. The models were adjusted for a comprehensive set of covariates, including age, sex, ethnicity, deprivation index, comorbidities, smoking status, and geographical region. Multiple imputation was used to handle missing data. A matched cohort analysis was also performed for the critical care cohort to further control for potential confounders.

Datasets

The study utilized the following key datasets:

  • QResearch: A large primary care database in England, covering approximately 20% of the population.
  • Intensive Care National Audit & Research Centre (ICNARC) Case Mix Programme: A national database for adult critical care in England, Wales, and Northern Ireland. For this study, only data from England was used.
  • Public Health England (PHE) COVID-19 testing data: National registry of COVID-19 RT-PCR positive test results.
  • Office of National Statistics (ONS) COVID-19 mortality data: Data on all deaths due to COVID-19 in England.

Key Insights and Ideas

  • B.1.1.7 as a significant risk factor for severe outcomes: The study provides robust evidence that B.1.1.7 was not just more transmissible but also increased the likelihood of severe disease requiring critical care and ultimately death.
  • The critical care threshold: A crucial insight is that while B.1.1.7 increased the chance of needing critical care, once a patient reached that threshold, the virus variant itself seemed to have little bearing on their survival within the critical care setting. This suggests that the severity of illness at admission, rather than the specific variant, became the dominant factor for in-hospital survival.
  • Importance of comprehensive adjustment: The study's strength lies in its ability to adjust for a wide array of demographic, socioeconomic, and clinical factors, which is essential for accurately assessing the independent effect of the virus variant.
  • SGTF as a reliable proxy: The use of SGTF as a proxy for B.1.1.7 was validated by its high correlation with the variant's prevalence in England at the time, allowing for large-scale analysis.

Key Results

  • Increased risk of CCU admission: Patients infected with B.1.1.7 had an adjusted hazard ratio (HR) of 2.15 (95% CI 1.75-2.65) for CCU admission compared to those with non-B.1.1.7 variants.
  • Increased risk of 28-day mortality: The adjusted HR for 28-day mortality in the primary care cohort was 1.65 (95% CI 1.36-2.01) for patients with B.1.1.7 compared to non-B.1.1.7.
  • No increased mortality in critical care: For patients already in critical care, the adjusted HR for mortality at the end of critical care was 0.91 (95% CI 0.76-1.09) for B.1.1.7 compared to non-B.1.1.7, indicating no significant difference.
  • Prevalence: In the primary care cohort, 59.4% of patients with a positive COVID-19 test had lineage B.1.1.7.

Limitations and Future Work

  • SGTF proxy limitations: While a good proxy, SGTF status was only identifiable for just over 50% of patients with a positive community COVID-19 test. Patients who died in care homes or were tested in the community were less likely to have SGTF identified, potentially introducing bias.
  • Unmeasured confounding: As with all observational studies, the possibility of unmeasured confounding factors remains, especially given the dynamic nature of the pandemic and the emergence of new variants.
  • Pre-testing deaths: The study could not observe patients who died before being tested, which could introduce bias if early mortality risk differs significantly between lineages.
  • Future work: The findings highlight the need for continued monitoring of new variants and their impact on disease severity and healthcare system capacity. The study's results emphasize the ongoing importance of public health measures to control exposure and infection.

Summary updated

Abstract

Wellcome Trust, National Institute for Health Research Oxford Biomedical Research Centre, and the Medical Sciences Division of the University of Oxford.
BibTeX
@inproceedings{patone2021mortality,
  author = {Martina Patone and Karen Thomas and Robert Alan Hatch and Pui San Tan and Carol Coupland and Weiqi Liao and Paul Mouncey and David A Harrison and Kathy Rowan and Peter Horby and Peter Watkinson and Julia Hippisley–Cox},
  title = {{Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study}},
  booktitle = {The Lancet Infectious Diseases},
  year = {2021},
  doi = {10.1016/s1473-3099(21)00318-2},
}
Figure